By GLP-1 StudioGLP1Consultant

The GLP-1 Studio Ecosystem

A connected family of GLP-1 platforms, built independently.

GLP-1 information is scattered across government documents, company announcements, research papers, media coverage, patient communities, and market activity.

I have built a growing group of focused platforms that organize it, surface the recurring questions, and give me a direct view into what patients, organizations, and industry leaders are looking for.

Media + Education

GLP1Studio.com

The parent platform behind the ecosystem.

Stories, science, reporting, interviews, and patient-led resources built for the GLP-1 community.

Visit Site →

Explore the platforms

GLP1Stocks.com

GLP-1 Sector Market Intelligence

A daily brief on every GLP-1 catalyst from the past 24 hours, from FDA decisions and trial readouts to legislation and earnings, so your team starts informed.

Visit Site →

GLP1Nation.com

Daily GLP-1 Industry News

The daily news source for the GLP-1 industry, covering the companies, regulators, payers, and access decisions that affect your business, sent each evening.

Visit Site →

GLP1Laws.com

GLP-1 Policy and Access Law Tracker

Track GLP-1 legislation and litigation by state in plain English, so your clinic or practice can stay ahead of the access rules that affect its operations.

Visit Site →

GLP1Meetups.com

Vetted GLP-1 Patient Community and Events

A safety-first community and events platform for GLP-1 patients, giving brands a verified, engaged audience to reach beyond anonymous forums and social groups.

Visit Site →

GLP1Powered.com

GLP-1 Products and Services Marketplace

A marketplace where patients find GLP-1 products and services in one place, and companies gain listings, featured placement, advertising, and introductions.

Visit Site →

GLP1Consultant.com

GLP-1 Consulting and Client Portal

A secure portal for GLP-1 consulting clients, offering scheduling, video sessions, hour-based billing, and document sharing in one professional environment.

Visit Site →

GLP1Strong.com

The STRONG Framework for Staff Training

A staff-training framework drawn from the STRONG white paper, helping your team build patient-friendly processes and reduce stigma for the people you serve.

Visit Site →

In Production

Platforms joining the ecosystem soon.

GLP1Magazine.com

In Production

The Quarterly GLP-1 Magazine

A quarterly digital magazine reaching an engaged GLP-1 audience, offering brands editorial visibility and a credible home for sponsored features.

Visit Site →

GLP1Museum.com

In Production

A History of the Field

An interactive timeline of three decades of GLP-1 history, giving your staff and customers a credible reference for the context behind the medicine.

Visit Site →

GLP1Coach.app

In Production

GLP-1 Coaching: Motivational Interviewing

A motivational interviewing model built for GLP-1 patients, giving clinics and employer programs a structured way to support behavior change in their members.

Visit Site →

Get listed, or build on the data.

Interested in featuring your organization on a GLP-1 Studio platform, or exploring API access to the data behind them? Let's talk.

Contact Amanda

Disclaimer:GLP-1 Consultant, a GLP-1 Studio LLC service, provides litigation consulting, expert witness, briefing and education services only. Amanda Bonello is not an attorney. Nothing on this site or in the client portal is medical, clinical, legal, regulatory, tax, accounting, or investment advice. No professional-client relationship of that kind is created, and no content here is a substitute for advice from a licensed professional. Please don't submit patient or protected health information. See our Terms and Privacy Policy. GLP-1 Consultant is a service of GLP-1 Studio LLC. Bright Rowan is an independent firm owned and operated by Christie Clutter. The scope, responsibilities, contracting parties, and fees for each engagement are defined in the applicable proposal and agreement. Compounded GLP-1 medications are not FDA-approved. The FDA has not reviewed compounded semaglutide, tirzepatide or other compounded GLP-1 products for safety, effectiveness or quality, and they are not equivalent to FDA-approved drugs. Information is accurate to the best of our knowledge at the time of writing. Medications, coverage rules and the news around them change quickly, and pages are not always updated the moment something changes. Views expressed by anyone other than GLP-1 Studio are their own. Their appearance here is not an endorsement, and it does not imply an affiliate, sponsorship or business relationship.